Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The role of T cell apoptosis in nervous system autoimmunity.
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Rituximab in paediatric onset multiple sclerosis: a case series.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Drug Safety Labeling Changes
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.

Pages